drugset / Trial / NCT03977493

IncobotulinumtoxinA (Xeomin) to Treat Focal Hand Dystonia

NCT03977493

RandomizedParallel-groupTriple-blindTreatment

Summary

This study is a multicenter, double-blind, randomized placebo controlled, parallel group, superiority trial in order to test the superiority of intramuscular injections of IncobotulinumtoxinA against placebo using a 1:1 allocation ratio.

Timeline

Start
2018-02-21
Primary completion
2027-12-31
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Botulinum toxin type A Protein / enzyme biologic 2.5 iu Intramuscular
Comparator Botulinum toxin type A Protein / enzyme biologic 40 iu Intramuscular

Indications